90 related articles for article (PubMed ID: 31109905)
1. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome.
Jindra P; Raida L; Karas M; Szotkowski T; Lysák D; Hrabětová M; Jungová A; Steinerová K; Faber E; Papajík T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):462-469. PubMed ID: 31109905
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.
Oran B; Cortes J; Beitinjaneh A; Chen HC; de Lima M; Patel K; Ravandi F; Wang X; Brandt M; Andersson BS; Ciurea S; Santos FP; de Padua Silva L; Shpall EJ; Champlin RE; Kantarjian H; Borthakur G
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1218-1226. PubMed ID: 27058617
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.
Helbig G; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kopińska A; Boral K; Grygoruk-Wiśniowska I; Stachowicz M; Karolczyk A
Ann Hematol; 2020 Aug; 99(8):1845-1853. PubMed ID: 32333156
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Chen YB; Li S; Lane AA; Connolly C; Del Rio C; Valles B; Curtis M; Ballen K; Cutler C; Dey BR; El-Jawahri A; Fathi AT; Ho VT; Joyce A; McAfee S; Rudek M; Rajkhowa T; Verselis S; Antin JH; Spitzer TR; Levis M; Soiffer R
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2042-8. PubMed ID: 25239228
[TBL] [Abstract][Full Text] [Related]
5. Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.
Bazarbachi A; Labopin M; Gedde-Dahl T; Remenyi P; Forcade E; Kröger N; Socié G; Craddock C; Bourhis JH; Versluis J; Yakoub-Agha I; Salmenniemi U; El-Cheikh J; Bug G; Esteve J; Nagler A; Ciceri F; Mohty M
Clin Cancer Res; 2023 Nov; 29(21):4441-4448. PubMed ID: 37603683
[TBL] [Abstract][Full Text] [Related]
6. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Othman J; Potter N; Ivey A; Jovanovic J; Runglall M; Freeman SD; Gilkes A; Thomas I; Johnson S; Canham J; Cavenagh J; Kottaridis P; Arnold C; Ommen HB; Overgaard UM; Dennis M; Burnett A; Wilhelm-Benartzi C; Dillon R; Russell NH
Blood; 2024 May; 143(19):1931-1936. PubMed ID: 38364112
[TBL] [Abstract][Full Text] [Related]
7. Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis.
Li Z; Liu Y; Wang Q; Chen L; Ma L; Hao S
Acta Haematol; 2019; 141(3):164-175. PubMed ID: 30808826
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITD
Pandya BJ; Burns LJ; Wang T; Xie B; Touya M; Spalding J; Block A; Kuperman G; Young C
Transplant Cell Ther; 2024 Apr; ():. PubMed ID: 38663769
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT.
Chen J; Labopin M; Pabst T; Zhang X; Jiang E; Tucci A; Cornelissen J; Meijer E; Khevelidze I; Polge E; Wu D; Mohty M; Gorin NC
Bone Marrow Transplant; 2023 Dec; 58(12):1322-1330. PubMed ID: 37640797
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.
Burke MJ; Wagner JE; Cao Q; Ustun C; Verneris MR
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1021-5. PubMed ID: 23567175
[TBL] [Abstract][Full Text] [Related]
11. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rücker FG; Du L; Luck TJ; Benner A; Krzykalla J; Gathmann I; Voso MT; Amadori S; Prior TW; Brandwein JM; Appelbaum FR; Medeiros BC; Tallman MS; Savoie L; Sierra J; Pallaud C; Sanz MA; Jansen JH; Niederwieser D; Fischer T; Ehninger G; Heuser M; Ganser A; Bullinger L; Larson RA; Bloomfield CD; Stone RM; Döhner H; Thiede C; Döhner K
Leukemia; 2022 Jan; 36(1):90-99. PubMed ID: 34316017
[TBL] [Abstract][Full Text] [Related]
12. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB;
J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061
[TBL] [Abstract][Full Text] [Related]
13. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study.
Shao R; Zhang Y; He J; Huang F; Fan Z; Yang K; Xu Y; Xu N; Luo Y; Deng L; Zhang X; Chen J; Han M; Li X; Yu S; Liu H; Liang X; Luo X; Shi P; Wang Z; Jiang L; Zhou X; Lin R; Chen Y; Tu S; Sun J; Wang Y; Liu Q; Xuan L
Signal Transduct Target Ther; 2023 Sep; 8(1):348. PubMed ID: 37704613
[TBL] [Abstract][Full Text] [Related]
14. Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
Moukalled N; Labopin M; Versluis J; Socié G; Blaise D; Salmenniemi U; Rambaldi A; Gedde-Dahl T; Tholouli E; Kröger N; Bourhis JH; Von Dem Borne P; Daguindau E; Forcade E; Nagler A; Esteve J; Ciceri F; Bazarbachi A; Mohty M
Am J Hematol; 2024 Mar; 99(3):360-369. PubMed ID: 38165072
[TBL] [Abstract][Full Text] [Related]
15. Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation.
Berman E; Maloy M; Devlin S; Jhanwar S; Papadopoulos E; Jakubowski A
Leuk Res; 2016 Jan; 40():33-7. PubMed ID: 26692109
[TBL] [Abstract][Full Text] [Related]
16. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with
Bazarbachi A; Bug G; Baron F; Brissot E; Ciceri F; Dalle IA; Döhner H; Esteve J; Floisand Y; Giebel S; Gilleece M; Gorin NC; Jabbour E; Aljurf M; Kantarjian H; Kharfan-Dabaja M; Labopin M; Lanza F; Malard F; Peric Z; Prebet T; Ravandi F; Ruggeri A; Sanz J; Schmid C; Shouval R; Spyridonidis A; Versluis J; Vey N; Savani BN; Nagler A; Mohty M
Haematologica; 2020 Jun; 105(6):1507-1516. PubMed ID: 32241850
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India.
Ganapule A; Nemani S; Korula A; Lakshmi KM; Abraham A; Srivastava A; Balasubramanian P; George B; Mathews V
J Glob Oncol; 2017 Dec; 3(6):773-781. PubMed ID: 29244983
[TBL] [Abstract][Full Text] [Related]
18. Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
Cremer A; Enssle JC; Pfaff S; Kouidri K; Lang F; Brandts C; Zeiher A; Cremer S; Steffen B; Serve H; Bug G
Ann Hematol; 2023 Oct; 102(10):2903-2908. PubMed ID: 37552323
[TBL] [Abstract][Full Text] [Related]
19. Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study.
Bazarbachi A; Labopin M; Moukalled N; Kröger N; Rautenberg C; Schetelig J; Finke J; Blau IW; Blaise D; Stelljes M; Eder M; Platzbecker U; Dreger P; Bethge W; Tischer J; Burns D; Sengeloev H; Brissot E; Giebel S; Nagler A; Ciceri F; Mohty M
Clin Cancer Res; 2024 May; 30(9):1778-1787. PubMed ID: 38514469
[TBL] [Abstract][Full Text] [Related]
20. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients.
Schmälter AK; Ngoya M; Galimard JE; Bazarbachi A; Finke J; Kröger N; Bornhäuser M; Stelljes M; Stölzel F; Tischer J; Schroeder T; Dreger P; Blau IW; Savani B; Giebel S; Esteve J; Nagler A; Schmid C; Ciceri F; Mohty M
Blood Cancer J; 2024 May; 14(1):76. PubMed ID: 38697960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
